Background:
India is home to approximately 148.88 million goats. Among the significant viral illnesses that affect goats, Peste-des-Petits Ruminants (PPR) and Goatpox hold importance. These diseases pose a substantial threat to the livelihoods of 70% of landless laborers, small and medium-scale farmers who depend on sheep and goat rearing. These diseases are prevalent within India and various regions globally, particularly across Africa, the Middle East, and Asia. The FAO and OIE have established a goal to eliminate PPR by the year 2030. In an effort to manage and eliminate both diseases through a singular immunization, we have merged previously developed live attenuated vaccines for both PPR and Goatpox. This approach aims to offer effective control and eradication of these two diseases through a single immunization. The technology is anticipated to streamline the efforts required in controlling both diseases, leading to savings in terms of time, finances, and labor:
Technology Details:
The PPR (Sungri/96) and Goatpox (Uttarkashi/1978) vaccine viruses underwent propagation in Vero cells and were quantified using Vero cells, following the established vaccine production procedures for each virus. Following in vitro quality assessments, the combined vaccine was formulated by blending equal quantities of both viruses, each with a titer of 105TCID50/mL, in LS stabilizer and then subjected to lyophilization. The efficacy of the vaccine technology was demonstrated in safeguarding goats when challenged with both PPR and Goatpox viruses. With the ongoing progress of the PPR control and eradication initiative, it is anticipated that this technology will witness demand within both domestic and international markets.